The stock of the BriaCell Therapeutics Corp. (BCTX) declined in the current market today. The stock traded at $8.23 per share declining 7.22% from the previously closed value. at the end of the last trading session, the stock closed at $8.87. The average volume of the stock traded in the trading session was around 1.98 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Recent press release by the company:
The company recently announced clinical findings and results from its lead clinical candidate Bria-IMT™. On 8th December 2021, a poster session was held during the 2021 San Antonio Breast Cancer Symposium.
The company said the rate of disease control was 25% in 4 patients and 30% in 23 patients for the monotherapy studies and 33% in 12 patients for the combination study. In several patients, it was observed that the tumor reduced completely, including those patients with 2+ HLA loci matches with Bria-IMT™ and Grade I/II that are moderately well-differentiated tumors. The disease control was seen in 1/2 and 4/6 patients in the monotherapy studies and 3/4 patients in the combination study of Grade I/II patients. According to the RECIST criteria, two patients were included with partial responses. Both patients with partial responses matched Bria-IMT at 2 HLA loci and both had Grade II disease.
Patients had already been heavily treated before and had a median of five or greater existing regimens. Overall the treatment was seen to be safe for the patients that suggest an additive or synergistic effect and support their strategy of combination study continuation. The data of both clinical and survival supports the benefits in the patients who match Bria-IMT™ at one or more HLA loci and those with Grade I/II tumors in the combined studies.
Effect on the stock:
The news is itself in favor of the company’s development but the trend of the stock is continuously on the decline for the past few months. The company’s financials were good in the previous quarter due to which the investors might be shying from investing in its stock.
Conclusion:
The company needs to strategize plans for the upcoming quarters to improve the performance of company. The closing quarter of 2021 will be crucial for its stock and investors’ decision to invest in its stock.
